Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 126 participants.

Also called NCT05199090

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05199090
  • EudraCT 2021-004449-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05199090. Randomized; double masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-05-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
Condition
Obesity
Intervention (Drug)
MBL949
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05199090
Content hash
bd1134721102c16e1a68886896323c759541c7a71633ce794224c8b5a98174ae